Stroke

Global Active Pharmaceutical Ingredients (APIs) Market Analysis/Forecast Report, 2022 & 2023-2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023

The "Active Pharmaceutical Ingredients (APIs) Market, Global Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Active Pharmaceutical Ingredients (APIs) Market, Global Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Global Active Pharmaceutical Ingredients (APIs) market was at US$ 190.5 Billion in 2022 and will surpass US$ 261.3 Billion by 2027, expanding at a CAGR of 6.52 from 2022 to 2027.
  • Active Pharmaceutical Ingredients (API) of good quality is core to manufacturing effective and safe essential drugs.
  • Some prominent players in the global active pharmaceutical ingredients market are Sanofi SA, F. Hoffmann-LA Roche Ltd, Pfizer, Abbott, Bayer AG, Merck & Co. Inc, Boehringer Ingelheim Gmbh, GlaxoSmithKline Plc, Novartis AG, Eli Lilly Company, and Teva Pharmaceutical.

Global Plant-Based Beverages Market Report 2022 to 2027: Industry Trends, Share, Size, Growth, Opportunities and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023

Plant-based beverages refer to healthy drinks that are manufactured and processed from plant materials, such as grains and seeds, and extracted in water.

Key Points: 
  • Plant-based beverages refer to healthy drinks that are manufactured and processed from plant materials, such as grains and seeds, and extracted in water.
  • Rice milk, soymilk, tea and coffee are some of the commonly available plant-based beverages.
  • Additionally, the increasing demand for plant-based supplements in the sports and nutrition industry is positively impacting the market growth.
  • The publisher provides an analysis of the key trends in each sub-segment of the global plant-based beverages market report, along with forecasts at the global, regional and country level from 2022-2027.

Prevencio Announces National Medicare Pricing for Company’s Three AI-Powered HART® Cardiac Blood Tests

Retrieved on: 
Tuesday, January 10, 2023

Prevencio, Inc. , The AI-Powered Cardiac Blood Test Company, today announced the Centers for Medicare & Medicaid Services (CMS) has set a National Medicare payment rate of $390.75 for each of the Company’s three lead proprietary HART® cardiac blood tests.

Key Points: 
  • Prevencio, Inc. , The AI-Powered Cardiac Blood Test Company, today announced the Centers for Medicare & Medicaid Services (CMS) has set a National Medicare payment rate of $390.75 for each of the Company’s three lead proprietary HART® cardiac blood tests.
  • The payment rates went into effect January 1, 2023, for Current Procedural Terminology (CPT) billing codes 0308U (for CADhs), 0309U (for HART CVE), and 0310U (for HART KD).
  • HART KD is the only available test to diagnose whether a child has Kawasaki disease.
  • In the U.S., it is the leading cause of death and kills more people than all cancers combined.

New Clinical Study Shows NeurOptics’ Neurological Pupil Index™, an Important Value for Assessing Brain Injury, is Unaffected by Clinical Intoxication

Retrieved on: 
Tuesday, January 10, 2023

A newly published clinical study shows that NeurOptics’ Automated Pupillometry and the Neurological Pupil index™ (NPi®) remain unaffected by clinical intoxication, and therefore can be used for rapidly screening emergency room patients for brain injury or neurological injuries regardless of intoxicated state.

Key Points: 
  • A newly published clinical study shows that NeurOptics’ Automated Pupillometry and the Neurological Pupil index™ (NPi®) remain unaffected by clinical intoxication, and therefore can be used for rapidly screening emergency room patients for brain injury or neurological injuries regardless of intoxicated state.
  • View the full release here: https://www.businesswire.com/news/home/20230110005401/en/
    NeurOptics’ automated pupillometer has emerged as an important technology that provides a reliable measurement of pupil size and reactivity, expressed as the Neurological Pupil index (NPi).
  • The results showed that although clinical intoxication did affect pupil size and other individual metrics of the pupillary light reflex, no statistical differences in the NPi were noted between those with intoxication versus control patients.
  • NPi remained unaffected by clinical intoxication and therefore can potentially be used for ED patient evaluation without risk of confounding by key intoxicants of abuse.

Researchers at University of Chicago and Johns Hopkins University to Better Measure Social Determinants of Health: the Social Vulnerability Metric (SVM)

Retrieved on: 
Thursday, January 12, 2023

CHICAGO, Jan. 12, 2023 /PRNewswire-PRWeb/ -- A new research study published in Health Services Research presents the development and validation of a new metric for social vulnerability. The breakthrough development of the social vulnerability metric (SVM) opens the door to a new approach to the estimation of social vulnerability from the ecological perspective. The SVM can serve as a tool for public health policy and practice, significantly impacting the understanding of an individual's risk based solely on their zip code.

Key Points: 
  • A new research study published in Health Services Research presents the development and validation of a new metric for social vulnerability.
  • The breakthrough development of the social vulnerability metric (SVM) opens the door to a new approach to the estimation of social vulnerability from the ecological perspective.
  • CHICAGO, Jan. 12, 2023 /PRNewswire-PRWeb/ -- A new research study published in Health Services Research presents the development and validation of a new metric for social vulnerability.
  • The breakthrough development of the social vulnerability metric (SVM) opens the door to a new approach to the estimation of social vulnerability from the ecological perspective.

GEM SLEEP Available in 40 States - Unlocking Access for the 24M Who Struggle to Find Sleep Apnea Solutions

Retrieved on: 
Thursday, January 12, 2023

MINNEAPOLIS, Jan. 12, 2023 /PRNewswire/ -- GEM Specialty Health, Inc., a digital specialty health company, announced the 40-state availability of GEM SLEEP, a comprehensive solution offering diagnosis, treatment and support for the 30 million people in the U.S. suffering from sleep apnea. The announcement comes alongside GEM SLEEP adding oral appliance solutions to the available treatment offerings in the Twin Cities through the Snoring & Sleep Apnea Dental Treatment Center (SSADTC).

Key Points: 
  • The announcement comes alongside GEM SLEEP adding oral appliance solutions to the available treatment offerings in the Twin Cities through the Snoring & Sleep Apnea Dental Treatment Center (SSADTC).
  • GEM SLEEP is a digital, one-stop solution that includes a virtual sleep clinic, a range of treatment options, and ongoing support to ensure a better night's sleep.
  • GEM SLEEP offers:
    Timely Access: Instead of waiting 2-3 months to get into a sleep clinic, GEM SLEEP offers a home sleep test within days.
  • GEM SLEEP improves the consumer experience and helps unlock the sleep apnea market for our provider, payer, employer, and device partners."

Ariadne Labs Announces 2022-2023 Spark Grant Recipients

Retrieved on: 
Wednesday, January 11, 2023

BOSTON, Jan. 11, 2023 /PRNewswire/ -- Ariadne Labs today announced five recipients of the Ariadne Labs Spark Grant innovation awards for the 2022-2023 year. The Spark Grant program provides support for new and early-stage ideas focused on making health care safer, more integrated, and more equitable for all patients. Now in its tenth year, the program has funded more than 20 projects. 

Key Points: 
  • Five grants will support early-stage ideas to make health care safer, more integrated, and more equitable
    BOSTON, Jan. 11, 2023 /PRNewswire/ -- Ariadne Labs today announced five recipients of the Ariadne Labs Spark Grant innovation awards for the 2022-2023 year.
  • The Spark Grant program provides support for new and early-stage ideas focused on making health care safer, more integrated, and more equitable for all patients.
  • The 2022-2023 recipients of the Ariadne Labs Spark Grant innovation awards are:
    Rose Molina, MD, MPH, Assistant Professor of Obstetrics, Gynecology, and Reproductive Biology at Harvard Medical School; Obstetrician-Gynecologist at Beth Israel Deaconess Medical Center and The Dimock Center; Core Faculty at Ariadne Labs
    Evidence suggests that individuals with limited English language proficiency experience lower quality maternal health care due to structural barriers and communication challenges.
  • In 2021 a Spark Grant funded initial work to develop a checklist to triage potential candidates for EVT.

EQS-News: Boost to adesso Italia’s growth: adesso acquires Italian company WebScience

Retrieved on: 
Thursday, February 2, 2023

Boost to adesso Italia’s growth: adesso acquires Italian company WebScience

Key Points: 
  • Boost to adesso Italia’s growth: adesso acquires Italian company WebScience
    The issuer is solely responsible for the content of this announcement.
  • Boost to adesso Italia’s growth: adesso acquires Italian company WebScience
    Dortmund/Milan, 19 January 2023 – adesso is acquiring a 100% stake in Italian company WebScience, based in Milan, Italy.
  • As the newly renamed adesso Italia, the team at WebScience and its clients will benefit from the synergies offered by the adesso Group’s Europe-wide business.
  • In this function, he will oversee the integration of WebScience and the fledgling adesso Italia into the Europe-wide adesso Group.

Sickle Cell 101 Unveils Its Innovative Approach in Digital Advocacy for a 'Rare' Disorder Through Social Media

Retrieved on: 
Wednesday, February 1, 2023

San Jose, California--(Newsfile Corp. - February 1, 2023) - Sickle Cell 101 , a non-profit organization, is using an innovative approach of digital advocacy to provide education and patient focused research for sickle cell.

Key Points: 
  • San Jose, California--(Newsfile Corp. - February 1, 2023) - Sickle Cell 101 , a non-profit organization, is using an innovative approach of digital advocacy to provide education and patient focused research for sickle cell.
  • With a community that reaches millions on social media spread across 115 countries, Sickle Cell 101 has made a significant impact in promoting awareness of both sickle cell disease and sickle cell trait at the grassroots level through their digital platform, rich in educational and research resources.
  • "Our goal at Sickle Cell 101 is to function as a global platform to educate, engage, and empower an underserved community," says Cassandra Trimnell, Founder and Executive Director of Sickle Cell 101.
  • Sickle Cell 101 continues to seek and transform the outlook and experiences for individuals living with sickle cell disease through education and empowerment and spurring research in this area.

Stand Up Therapeutics and VectorBuilder Announced the Initiative to Supply the Initial Paraplegic Patient's Gene Therapy Materials

Retrieved on: 
Wednesday, January 11, 2023

Seoul, South Korea--(Newsfile Corp. - January 11, 2023) - Stand Up Therapeutics Co., Ltd. has emerged as a gene therapy firm where Stand Up Therapeutics and VectorBuilder announced the initiative to supply the initial paraplegic patient's gene therapy materials. According to Stand Up Therapeutics, VectorBuilder will create and distribute gene therapy products designed by Stand Up Therapeutics in the future under this arrangement. The objective is to control the global market.

Key Points: 
  • Stand Up Therapeutics said that it had inked a contract with VectorBuilder Inc., a global leader in gene delivery technologies, to produce a GMP-grade gene delivery system.
  • Seoul, South Korea--(Newsfile Corp. - January 11, 2023) - Stand Up Therapeutics Co., Ltd. has emerged as a gene therapy firm where Stand Up Therapeutics and VectorBuilder announced the initiative to supply the initial paraplegic patient's gene therapy materials.
  • According to Stand Up Therapeutics, VectorBuilder will create and distribute gene therapy products designed by Stand Up Therapeutics in the future under this arrangement.
  • Chief Scientist of VectorBuilder Bruce Lahn stated, "VectorBuilder is particularly interested in Stand Up Therapeutics' gene therapy for the global treatment of paralysis.